Long-term trend of quality-adjusted time without symptoms or toxicities (Q-TWiST) of nivolumab+ipilimumab (N+I) versus sunitinib (SUN) for the first-line treatment of advanced renal cell carcinoma (aRCC) Meeting Abstract
| Authors: | Motzer, R. J.; Choueiri, T. K.; May, J.; Kwon, Y.; Rusibamayila, N.; Botteman, M.; Hamilton, M.; Ejzykowicz, F.; Cella, D. |
| Abstract Title: | Long-term trend of quality-adjusted time without symptoms or toxicities (Q-TWiST) of nivolumab+ipilimumab (N+I) versus sunitinib (SUN) for the first-line treatment of advanced renal cell carcinoma (aRCC) |
| Meeting Title: | 2021 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2021 Jun 4-8 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-05-20 |
| Language: | English |
| ACCESSION: | WOS:000708120604022 |
| DOI: | 10.1200/JCO.2021.39.15_suppl.6568 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 6568 -- Source: Wos |
